Biotech Values

[genisi]

Urche, when I wrote

the question raised by urche in #msg-75751678

I referred to this question:

However, I find it odd that the study apparently did not study the famous group of people with the Apo A-1 Milano variant who I thought clearly had a demonstrated profile with higher than normal HDL and lower than normal cardiovascular risk.

Regarding your other question on HDL subtypes, it is not a question addressed in the Lancet genetic study as they tested SNPs that are associated with elevated HDL-C plasma level and not a spesific HDL subtype. Their data implies that raising HDL-C plasma level alone is not going to be clinically useful. Perhaps targeting a specific subtype or changing HDL molecule from pro-inflammatory HDL to anti-inflammatory HDL instead of raising HDL-C is the way to go, but this is far beyond my knowledge.